Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090266 · ClinicalTrials.gov registry record · Phase 1
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A Phase 1 study of Cancer and Non-Small Cell Lung Cancer, sponsored by OncoResponse.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 4
- Study locations
NCT06090266 is a Phase 1 study of Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by OncoResponse. The registered enrollment target is 168 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06090266, a Phase 1 study of Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by OncoResponse.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG OR502
Study Locations (4)
Texas
- NEXT Austin - Austin
- NEXT Dallas - Irving
- NEXT Oncology - San Antonio
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090266
The ClinicalTrials.gov registry entry for NCT06090266 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is OncoResponse, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06090266 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06090266 about?
NCT06090266 is a clinical study titled "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents". This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjec...
What is the current status of trial NCT06090266?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2023-10-24. Estimated completion is 2027-02-01.
What conditions does trial NCT06090266 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Cancer, Malignant Neoplasm.
What interventions are being tested in trial NCT06090266?
The interventions under investigation include: Cemiplimab (DRUG), OR502 (DRUG).
Who is sponsoring clinical trial NCT06090266?
This trial is sponsored by OncoResponse, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090266 being conducted?
This trial has 4 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.